145 research outputs found
Colonization by Escherichia coli strains with increased minimal inhibitory concentration for cefiderocol: When resistance anticipates drug use.
n/
Escherichia coli Nissle 1917 in ulcerative colitis treatment: Systematic review and meta-analysis
Background & Aims: Escherichia coli Nissle 1917 (EcN) has been recommended as a therapeutic tool for ulcerative colitis (UC) treatment. However, to date, no meta-analysis has been performed on this topic. Methods. We performed a literature search on PubMed, MEDLINE, Science Direct and EMBASE. We evaluated success rates for induction of remission, relapse rates and side effects, expressed as Intention-To-Treat. Odd ratios (OR), pooled OR and 95% confidence intervals (CI) were calculated, based on the Mantel-Haenszel method. Heterogeneity was assessed by using the χ2 and I2 statistics and, if present, a random-effects model was adopted. Results. We selected six eligible trials, with 719 patients, 390 assigned to the study group and 329 to the control group. EcN induced remission in 61.6% of cases, while in the control group (mesalazine) the remission was achieved in 69.5% of cases, with a mean difference of 7.9%. The pooled OR was 0.92 (95% CI 0.15-9.66, p=0.93). A single study showed a better performance of EcN than the placebo. A relapse of the disease occurred in 36.8% in the EcN group and in 36.1% in the control group (mesalazine), with a mean difference of 0.8%, OR=1.07, with a 95% CI of 0.70-1.64 (p=0.74). Side effects were comparable (OR=1.44, 95% CI 0.80-2.59, p=0.22). Conclusions. EcN is equivalent to mesalazine in preventing disease relapse, thus confirming current guideline recommendations. EcN seems to be as effective as controls in inducing remission and therefore, its use cannot be recommended as in one study the comparison was performed against placebo. Further studies may be helpful for this subject
Surface Texturing of n- and p-Doped c-Si Using a Novel Plasma Chemical Texturing Process
Abstract n- and p-doped c-Si (100) are textured by a SF 6 /O 2 plasma chemical etching, under conditions avoiding ion bombardment. The study of the effects of plasma parameters on morphology and on surface reflectance of textured c-Si reveals a strong impact of silicon doping on texturing characteristics. SF 6 /O 2 plasma etches anisotropically n-type c-Si creating a square-based hillock-like morphology with a surface reflectivity of 6%. Conversely, for p-type Si, a H 2 plasma pretreatment is necessary to activate silicon etching and obtain a nano-textured surface with a reflectivity of 16%
Demonstration of improved charge transfer in graphene/Au nanorods plasmonic hybrids stabilized by benzyl thiol linkers
Hybrids based on graphene decorated with plasmonic gold (Au) nanostructures are being investigated as possible materials combination to add to graphene functionalities of tunable plasmon resonance and enhanced absorption at selected wavelength in the visible-near-infrared region of the spectrum. Here, we report a solution drop-casting approach for fabricating stable hybrids based on chemical vapor deposition (CVD) graphene and Au nanorods, which are able to activate effective charge transfer from graphene. We demonstrate that CVD graphene functionalization by benzyl thiol (BZT) provides the linker to strong anchoring, via S-Au bonds, Au nanorods to graphene. Optical measurements by spectroscopic ellipsometry give evidence of the introduction of plasmon resonances at 1.85 and 2.25 eV in the Au nanorods/BZT/graphene hybrids, which enable surface enhanced Raman scattering (SERS) detection. Furthermore, an effective electron transfer from graphene to Au nanorods, resulting in an enhancement of p-type doping of graphene with a consequent decrease of its sheet resistance, is probed by Raman spectroscopy and corroborated by electrical measurements
Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C
Concomitant inflammatory bowel disease (IBD) and hepatitis C virus (HCV) infection is a relevant comorbidity since IBD itself exposes to a high risk of liver damage. We aimed to evaluate liver stiffness (LS) in IBD-HCV after antiviral treatment. We enrolled IBD patients with HCV. All patients at baseline underwent LS measurement by elastography. Patients who were eligible for antiviral therapy received direct antiviral agents (DAAs) and sustained viral response was evaluated at the 12th week. A control group was selected within IBD patients without HCV. One year later, all IBD-HCV patients and controls repeated LS measurement. Twenty-four IBD-HCV patients and 24 IBD controls entered the study. Only twelve out of 24 received DAAs and all achieved sustained viral response (SVR). All IBD subjects were in remission at enrollment and maintained remission for one year. After one year, IBD patients who eradicated HCV passed from a liver stiffness of 8.5 ± 6.2 kPa to 7.1 ± 3.9, p = 0.13. IBD patients who did not eradicate HCV worsened liver stiffness: from 7.6 ± 4.4 to 8.6 ± 4.6, p = 0.01. In the IBD control group, stiffness decreased from 7.8 ± 4.4 to 6.0 ± 3.1, p < 0.001. In conclusion, HCV eradication is able to stop the evolution of liver fibrosis in IBD, while failure to treat may lead to its progression. A stable IBD remission may improve LS even in non-infected subjects
Wet chemical nitridation of GaAs (100) by hydrazine solution for surface passivation
A mild wet nitridation procedure using hydrazine-based solutions has been developed for GaAs (100) surface passivation. Both x-ray photoelectron spectroscopy and spectroscopic ellipsometry show that this nitridation procedure results in a very thin, coherent, and homogeneous GaN layer that is very stable in air. Photoluminescence data show a strong enhancement of the intensity as compared to that of an as-cleaned GaAs sample, indicating that this nitrided layer provides both chemical and electronic passivation of GaAs surfaces. The chemical mechanism of nitridation is discusse
Chemoprevention of inflammation-related colorectal cancer by silymarin-, acetyl-11-keto-beta-boswellic acid-, curcumin- and maltodextrin-enriched dietetic formulation in animal model
On the basis of preliminary in vitro experience, we assessed whether an enriched nutritional formulation with estrogen receptor (ER)-beta agonist and anti-inflammatory properties may prevent inflammation-associated colorectal cancer (CRC) in an animal model. Study sample enclosed 110 C57BL/6J male mice. Forty underwent dietary supplement safety assessment (20 standard diet and 20 enriched formulation). Seventy were treated with azoxymethane (AOM)/dextran sulfate sodium and divided into two groups: 35 received standard diet and 35 enriched formulation (curcumin, boswellic acids, silymarin and maltodextrins). Miniature colonoscopy demonstrated colitis and solid lesion development in five mice/group 100 days after first AOM injection. Mice were killed after 10 days. In each group, four subgroups received intraperitoneal bromodeoxyuridine (BrdU) injection at 24th/48th/72nd/96th hour before killing. Anti-inflammatory effect and chemoprevention were evaluated by lesion number/size, histological inflammation/dysplasia/neoplasia assessment, pro-inflammatory cytokine messenger RNA (mRNA), ER-beta/ER-alpha/BrdU immunohistochemistry and TUNEL immunofluorescence. Standard formulation assumption was associated with colon shortening compared with enriched one (P = 0.04), which reduced solid lesion number and size (P < 0.001 for both), histological inflammation score (P = 0.04), pro-inflammatory cytokine mRNA expression (P < 0.001), number of low-grade dysplasia (LGD; P = 0.03) and high-grade dysplasia (P < 0.001) areas. CRC was observed in 69.6% in standard and 23.5% in enriched formulation assuming animals (P < 0.001). Enriched formulation induced lower ER-alpha expression in CRC (P < 0.001) and higher ER-beta expression in LGD (P < 0.001) being associated to higher epithelial turnover (BrdU; P<0.001) in normal mucosa and increased apoptosis in LGD and CRC (P < 0.001 for both). Our results are promising for a successful anti-inflammatory and chemopreventive effect of enriched formulation in CRC arising from inflamed tissue
Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
BACKGROUND
In recent years, an increasing prevalence of obesity in inflammatory bowel disease
(IBD) has been observed. Obesity, moreover, has been directly correlated with a
more severe clinical course and loss of response to treatment.
AIM
To assess the prevalence and associated factors of obesity in IBD.
METHODS
We collected data about IBD disease pattern and activity, drugs and laboratory
investigations in our center. Anthropometric measures were retrieved and obesity
defined as a body mass index (BMI) > 30. Then, we compared characteristics of
obese vs non obese patients, and Chi-squared test and Student’s t test were used
for discrete and continuous variables, respectively, at univariate analysis. For
multivariate analysis, we used binomial logistic regression and estimated odd
ratios (OR) and 95% confidence intervals (CI) to ascertain factors associated with
obesity.
RESULTS
We enrolled 807 patients with IBD, either ulcerative colitis (UC) or Crohn’s
disease (CD). Four hundred seventy-four patients were male (58.7%); the average
age was 46.2 ± 13.2 years; 438 (54.2%) patients had CD and 369 (45.8%) UC. We
enrolled 378 controls, who were comparable to IBD group for age, sex, BMI,
obesity, diabetes and abdominal circumference, while more smokers and more
subjects with hypertension were observed among controls. The prevalence of
obesity was 6.9% in IBD and 7.9% in controls (not statistically different; P = 0.38).
In the comparison of obese IBD patients and obese controls, we did not find any
difference regarding diabetes and hypertension prevalence, nor in sex or smoking
habits. Obese IBD patients were younger than obese controls (51.2 ± 14.9 years vs
60.7 ± 12.1 years, P = 0.03). At univariate analysis, obese IBD were older than
normal weight ones (51.2 ± 14.9 vs 44.5 ± 15.8, P = 0.002). IBD onset age was earlier
in obese population (44.8 ± 13.6 vs 35.6 ± 15.6, P = 0.004). We did not detect any
difference in disease extension. Obese subjects had consumed more frequently
long course of systemic steroids (66.6% vs 12.5%, P = 0.02) as well as antibiotics
such as metronidazole or ciprofloxacin (71.4% vs 54.7%, P = 0.05). No difference
about other drugs (biologics, mesalazine or thiopurines) was observed. Disease
activity was similar between obese and non obese subjects both for UC and CD.
Obese IBD patients suffered more frequently from arterial hypertension, type 2
diabetes, non-alcoholic fatty liver disease. Regarding laboratory investigations,
obese IBD patients had higher levels of triglyceridemia, fasting blood glucose,
gamma-glutamyl-transpeptidase. On multivariate analysis, however, the only
factor that appeared to be independently linked to obesity in IBD was the high
abdominal circumference (OR = 16.3, 95%CI: 1.03-250, P = 0.04).
CONCLUSION
Obese IBD patients seem to have features similar to general obese population, and
there is no disease-specific factor (disease activity, extension or therapy) that may
foster obesity in IBD
- …